Drug Type Antibody drug conjugate (ADC) |
Synonyms GSK5764227, GSK’227, HS 20093 + [1] |
Target |
Mechanism CD276 inhibitors(CD276 antigen inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationBreakthrough Therapy (CN), Breakthrough Therapy (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Small Cell Lung Cancer | Phase 3 | - | 30 Sep 2024 | |
Small cell lung cancer recurrent | Phase 3 | CN | 04 Jul 2024 | |
Extensive stage Small Cell Lung Cancer | Phase 2 | CN | 01 Mar 2024 | |
Esophageal Carcinoma | Phase 2 | CN | 25 Jan 2024 | |
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 13 Dec 2023 | |
Metastatic castration-resistant prostate cancer | Phase 2 | CN | 13 Dec 2023 | |
Squamous Cell Carcinoma of Head and Neck | Phase 2 | CN | 04 Dec 2023 | |
Refractory Osteosarcoma | Phase 2 | CN | 08 Jun 2023 | |
Bone Cancer | Phase 1 | - | 20 Dec 2024 | |
Osteosarcoma | Phase 1 | - | 20 Dec 2024 |
Phase 2 | Osteosarcoma, Recurrent Last line | 34 | zmbehnbxgc(fjoaxargvy) = hpkqwsyzon mksgamjowk (wpimvfzecs ) View more | Positive | 24 May 2024 | ||
(8.0 mg/kg) | pnxwzavjcj(egplrcmhmj) = egxtlwxryx hbpccstozq (lwrcxphsfq ) | ||||||
Phase 1 | 56 | (8.0 mg/kg Q3W) | xbyluxbhgk(gooidexblu) = tlnwvusznf moycgubtfl (rwgjltsgpl ) View more | Positive | 24 May 2024 | ||
(10.0 mg/kg Q3W) | xbyluxbhgk(gooidexblu) = ilgtqaquxg moycgubtfl (rwgjltsgpl ) View more | ||||||
Phase 1 | 53 | fexcnqrwvh(hdxaocxipq) = aauqixlzly hmrladgguc (eovanlolde ) View more | Positive | 31 May 2023 | |||
(SCLC) | zzwjyvwhxb(ndbbxzfspx) = hihejmgypx zftqlqyfru (twwdlaydic ) View more |